CytoMed Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio106.38146.86
P/B Ratio5.926.63
Price/Tangible Book6.046.64
Enterprise Value Ratios
EV/Revenue93.59127.72
Profitability & Returns
Return on Equity (ROE)-0.25%-0.70%-1.97%-1.34%-1.62%
Return on Assets (ROA)-0.17%-0.27%-0.21%-0.22%-0.24%
Return on Capital Employed (ROCE)-0.33%-0.33%-1.75%-0.55%-1.21%
Leverage & Solvency Ratios
Debt/Equity0.050.047.201.266.26
Liquidity Ratios
Current Ratio9.8914.080.601.120.54
Quick Ratio8.3912.830.390.860.34
Efficiency Ratios
Asset Turnover0.040.060.060.020.02
Inventory Turnover0.040.010.020.010.03
Yield & Distribution Ratios
Earnings Yield-0.05%-0.06%
FCF Yield-0.08%-0.05%
Buyback Yield-0.09%-0.34%-0.14%-0.18%-0.06%